Paloma Partners Management CO Ironwood Pharmaceuticals Inc Transaction History

Paloma Partners Management CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$9.05 - $12.2 $205,217 - $276,647	-22,676 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.99 - $10.74 $203,857 - $243,540	22,676 New	22,676 $204,000
Q4 2019 Feb 14, 2020	SELL	$8.22 - $14.0 $82,660 - $140,784	-10,056 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$8.59 - $10.96 $86,381 - $110,213	10,056 New	10,056 $86,000
Q2 2019 Aug 14, 2019	SELL	$9.8 - $12.89 $625,583 - $822,833	-63,835 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$8.27 - $12.73 $527,915 - $812,619	63,835 New	63,835 $864,000
Q2 2018 Aug 14, 2018	SELL	$11.83 - $16.2 $731,235 - $1 Million	-61,812 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$11.13 - $13.63 $135,518 - $165,958	-12,176 Reduced 16.46%	61,812 $954,000
Q4 2017 Feb 14, 2018	SELL	$12.16 - $14.58 $405,888 - $486,665	-33,379 Reduced 31.09%	73,988 $1.11 Million
Q3 2017 Nov 14, 2017	BUY	$12.07 - $14.87 $1.3 Million - $1.6 Million	107,367	107,367 $1.69 Million

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $645M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

Stay updated on Paloma Partners Management CO with notifications on news.